Use of lectin-functionalized particles for oral immunotherapy
Open accessAbstract
Immunotherapy, in recent times, has found its application in a variety of immunologically mediated diseases. Oral immunotherapy may not only increase patient compliance but may, in particular, also induce both systemic as well as mucosal immune responses, due to mucosal application of active agents. To improve the bioavailability and to trigger strong immunological responses, recent research projects focused on the encapsulation of drugs and antigens into polymer particles. These particles protect the loaded antigen from the harsh conditions in the GI tract. Furthermore, modification of the surface of particles by the use of lectins, such as Aleuria aurantia lectin, wheatgerm agglutinin or Ulex europaeus-I, enhances the binding to epithelial cells, in particular to membranous cells, of the mucosa-associated lymphoid tissue. Membranous cell-specific targeting leads to an improved transepithelial transport of the particle carriers. Thus, enhanced uptake and presentation of the encapsulated antigen by antigen-presenting cells favor strong systemic, but also local, mucosal immune responses.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
0 of 170 cited sources checked · 0 supported · 0 flagged
- Premisecitation
The size range of particles able to cross the intestinal barrier is 700 nm to 10 μm.
“The size of particles able to cross the intestinal barrier has been narrowed down to ranges between 700 nm and 10 μm [40].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [40] source
Not checked in the free run.
- Premisenone given
Surface modification of particles with lectins such as Aleuria aurantia lectin, wheatgerm agglutinin, or Ulex europaeus-I increases binding to epithelial cells, especially membranous cells of mucosa-associated lymphoid tissue.
“Furthermore, modification of the surface of particles by the use of lectins, such as Aleuria aurantia lectin, wheatgerm agglutinin or Ulex europaeus-I, enhances the binding to epithelial cells, in particular to membranous cells, of the mucosa-associated lymphoid tissue.”
Quote in the paperNot a substantial claim - Interpretationreasoning
Targeting membranous cells specifically improves transepithelial transport of particle carriers.
“Membranous cell-specific targeting leads to an improved transepithelial transport of the particle carriers.”
Quote in the paperSubstantial claim - Premisecitation
Slight differences in NP size affect the availability of encapsulated drugs in the circulation.
“Additionally, slight differences of NP size have an impact on the availability of encapsulated drugs in the circulation.”
Quote in the paperNot a substantial claim0 of 2 sources checked - Premisecitation
Enterocytes and M cells are the two cell types in intestinal mucosa responsible for uptake of particulate structures.
“In the intestinal mucosa, two different cell types are responsible for the uptake of particulate structures: enterocytes and ‘membranous’ or ‘microfold’ cells (M cells).”
Quote in the paperSubstantial claim0 of 2 sources checked
- Interpretationcitation
A very small difference in particle size determines whether particles only bind to cells or are internalized.
“Thus, a very small difference in particle size is decisive for either sole cell-binding or even internalization [41].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [41] source
Not checked in the free run.
- Premisecitation
PLGA and PLA are often used for oral immunotherapy particles because of their carrier properties and adjuvant effects.
“Polymer particles used for oral immunotherapy are often made from polylactide-co-glycolide (PLGA) or polylactide (PLA) not only due to their special carrier properties, but also because of their adjuvant effects [2].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [2] source
Not checked in the free run.
- Premisecitation
M cells are mainly responsible for uptake of intact particulate structures.
“They are mainly responsible for the uptake of intact, particulate structures [28].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [28] source
Not checked in the free run.
- Interpretationreasoning
Enhanced uptake and presentation of encapsulated antigen by antigen-presenting cells promotes strong systemic and local mucosal immune responses.
“Thus, enhanced uptake and presentation of the encapsulated antigen by antigen-presenting cells favor strong systemic, but also local, mucosal immune responses.”
Quote in the paperSubstantial claim - Premisecitation
MPs larger than 5 μm remain trapped in Peyer's patches for up to 35 days.
“In contrast, MPs greater than 5 μm remain trapped in the Peyers patches for up to 35 days [39].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [39]
Not checked in the free run.
- Premisenone given
Particle size determines uptake and retention time at M-cell sites.
“Furthermore, the particles’ size determines not only the uptake, but also the retention time at M-cell sites.”
Quote in the paperSubstantial claim - Premisereasoning
The type and intensity of the elicited immune response are influenced by characteristics of the particle carrier.
“In addition, the type and intensity of the elicited immune response are also influenced by th character istics of the particle carrier.”
Quote in the paperSubstantial claim - Premisecitation
Incorporation of fluorescent labeled peptides and iron oxide allows encapsulated antigens to be microscopically tracked without loss of vaccine function.
“By the incorporation of fluorescent labeled peptides and the inclusion of iron oxide, encapsulated antigens can be microscopically tracked without the loss of vaccine function.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [68] source
Not checked in the free run.
- Premisecitation
Uptake of NPs may result in production and release of pro-inflammatory cytokines such as IL-1, IL-5, IL-8, IL-10, IL-18, and TNF-α.
“The uptake of NPs may result in the production and release of pro-inflammatory cytokines, such as IL-1, IL-5, IL-8, IL-10, IL-18 and TNF-α [62,63].”
Quote in the paperNot a substantial claim0 of 2 sources checked - Premisecitation
Fluorescent MPs (2-8 μm) attach nonspecifically to the surface of APCs.
“Fluorescent MPs (2–8 μm) were found to attach to the cell surface of APCs in a nonspecific manner [2].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [2] source
Not checked in the free run.
- Premisecitation
Subcutaneously applied NPs encapsulating Bet v1 induced comparable IgG1, IgG2a, and IgG2b titers in BALB/c mice as subcutaneous treatment with allergen plus aluminum.
“Subcutaneously applied NPs encapsulating the birch pollen allergen Bet v1 induced comparable IgG1, IgG2a and IgG2b titers in BALB/c mice as subcutaneous treatment with allergen combined with aluminum [55].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [55] source
Not checked in the free run.
- Premisecitation
Semete et al. observed no increase in cytokine production.
“Semete et al., however, observed no increase in cytokine production [64].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [64] source
Not checked in the free run.
- Premisecitation
A dimannosyl ligand used for liposomal vesicles targeting, containing TLR-2 ligand Pam2CAG and peptide sequences of ERbB2 and Th-helper epitopes, eradicated ErbB2-expressing tumors more efficiently in an artificial mouse tumor model.
“When a dimannosyl ligand was used for liposomal vesicles targeting, which contained the Toll-like receptor (TLR)-2 ligand Pam2CAG for strong immune stimulation and further peptide sequences of ERbB2 and Th-helper epitopes, tumors expressing ErbB2 were eradicated more efficiently in an artificial mouse tumor model [71].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [71] source
Not checked in the free run.
- Premisecitation
Coating polystyrene particles with poloxamer, which increases hydrophilicity, decreased GI uptake.
“Coating of PS particles with poloxamer, which increases hydrophilicity, was demonstrated to decrease the GI uptake [47].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [47] source
Not checked in the free run.
- Premisecitation
Intraperitoneal immunization with PLGA MPs loaded with pollen extract induced a Th1-dominant immune response including IgG2a antibodies and IFN-γ production by spleen cells in animal studies.
“In animal studies, intraperitoneal immunization with PLGA MPs loaded with pollen extract even induced a Th1-dominant immune response including IgG2a antibodies and IFN-γ production by spleen cells [56,57].”
Quote in the paperSubstantial claim0 of 2 sources checked - Interpretationreasoning
Particle characteristics such as size and surface charge influence interaction, uptake, and distribution by intestinal epithelial cells.
“Therefore, the characteristics of particles, such as size and surface charge, influence the interaction, uptake and distribution by intestinal epithelial cells.”
Quote in the paperSubstantial claim - Premisecitation
Uptake of NPs and intensity of antigen presentation by APCs can be modulated by substances bound to the particle surface that specifically target APCs, such as DC-SIGN antibodies.
“The uptake of NPs and the intensity of antigen presentation by APCs can be modulated by the use of substances bound to the particle surface, specifically targeting APCs, such as DC-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN) antibodies.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [68] source
Not checked in the free run.
- Premisecitation
NPs made of polymers with different hydrophilic properties showed a similar decrease in GI uptake.
“A similar effect was shown for NPs made of polymers with different hydrophilic properties [48].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [48] source
Not checked in the free run.
- Premisecitation
PLGA and PLA particles have a negative surface charge.
“A further property of PLGA and PLA particles is their negative surface charge [44–45].”
Quote in the paperSubstantial claim0 of 2 sources checked - Premisecitation
Surface modification with a DC-SIGN-specific antibody did not enhance uptake and presentation of MP encapsulated antigens.
“Interestingly, the surface modification with a DC-SIGN-specific antibody did not enhance uptake and presentation of MP encapsulated antigens.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [68] source
Not checked in the free run.
- Interpretationreasoning
Because epithelial cells and mucus of the GI tract are negatively charged, uptake of PLGA and PLA particles without surface modification may be poor.
“As epithelial cells and mucus of the GI tract are negatively charged, the uptake of PLGA and PLA particles without surface modification may be poor.”
Quote in the paperSubstantial claim- Rests on an assumption: Epithelial cells and mucus of the gastrointestinal tract carry a negative charge.
- Premisecitation
With DC-specific targeting, antigen-specific cellular responses can be stimulated at 10-100-fold lower particle concentrations than with nontargeted NPs.
“With this DC-specific targeting approach, antigen-specific cellular responses can be stimulated at 10–100-fold lower particle concentrations than with nontargeted NPs [68].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [68] source
Not checked in the free run.
- Interpretationreasoning
PLGA particles may be beneficial for immunomodulation, especially when the immune system is biased toward a Th2 environment such as in allergic diseases.
“Therefore, the use of PLGA particles for immunomodulating purposes may be beneficial, especially in situations where the immune system is biased towards a Th2 environment, such as in allergic diseases.”
Quote in the paperSubstantial claim- Rests on an assumption: Aluminum hydroxide triggers a Th2-driven immune response.
- Premisecitation
Phagocytosis by macrophages can be increased by coating microspheres with targeting substances such as wheatgerm agglutinin, arginine-glycine-aspartic acid-containing peptide, or mannose-polyethylene glycol(PEG)3-NH2.
“Interestingly, the capacity of phagocytosis by macrophages can be increased by coating microspheres with targeting substances, such as wheatgerm agglutinin (WGA), arginine–glycine–aspartic acid-containing peptide or mannose-polyethylene glycol(PEG)3-NH2 [67].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [67] source
Not checked in the free run.
- Premisenone given
The longevity of protective effects after vaccination is determined by induction of a memory response.
“After the induction of the first immune responses, the longevity of the protective effects after vaccination is determined by the induction of a memory response.”
Quote in the paperSubstantial claim - Interpretationcitation
Combining mannose receptor and TLR targeting beneficially affects binding to APCs and stimulation of cellular immune responses.
“This combination of mannose receptor and TLR targeting beneficially affects the binding to APCs and the stimulation of cellular immune responses.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [71] source
Not checked in the free run.
- Interpretationreasoning
Fine-tuning particle properties and design by choosing size and hydrophilicity is substantial for optimizing uptake and the resulting immunological response.
“Therefore it is obvious that a ‘fine-tuning’ of particle properties and design by the choice of size and hydrophilicity is substantial for optimizing the uptake and the resulting immunological response.”
Quote in the paperSubstantial claim - Premisecitation
In mice, two gavages of WGA-coated allergen-loaded PLGA microspheres resulted in higher allergen-specific IgG production than uncoated particles.
“After two gavages of WGA-coated microspheres, mice revealed a higher allergen-specfic IgG production compared with feedings of uncoated particles [108].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [108] source
Not checked in the free run.
- Premisecitation
Incorporation of doxorubicin into PLGA nanospheres significantly reduced doxorubicin-induced cardiotoxicity.
“incorporation of doxorubicin into PLGA nanospheres significantly reduced the doxorubicin-induced cardiotoxicity [74].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [74] source
Not checked in the free run.
- Premisecitation
Mice orally immunized with LTA-coated NPs developed significantly higher Th1 response (IgG2a/IgG1 ratio) than intramuscular alum-based HBsAg injections.
“mice immunized orally with these LTA-coated NPs developed a significantly higher Th1 response by means of IgG2a/IgG1 production ratio compared with intra muscular aluminum hydroxide-based HBsAg injections.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [114] source
Not checked in the free run.
- Premisecitation
In birch pollen-sensitized mice, oral treatment with WGA-coated allergen-loaded microspheres did not induce allergen-specific isotype switch to IgG2a or IFN-γ production compared to plain microspheres.
“when the efficacy of WGA-coated allergen-loaded microspheres was evaluated in birch pollen-sensitized mice, oral treatment did not induce an allergen-specific isotype switch towards IgG2a or the production of the Th1 cytokine IFN-γ in comparison to gavages of plain microspheres [74].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [74] source
Not checked in the free run.
- Premisecitation
Many enteropathogenic and nonenteropathogenic pathogens are primarily taken up by M cells.
“A number of enteropathogenic microorganisms, such as Vibrio cholerae [85,86], Salmonella typhimurium [87,88], Shigella flexneri [89–91], Yersinia pseudotuberculosis and Yersinia enterocolotica [92–94], and reoviruses [95], but also nonenteropathogenic pathogens, such as influenza virus A [96], or human immunodeficiency virus-1 (HIV-1) [97], are primarily taken up by M cells, as reviewed by Corr et”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [98] source
Not checked in the free run.
- Premisecitation
PEGylation of glycan-modified liposomes interfered with targeting potential to DCs.
“However, PEGylation of glycan-modified liposomes interfered with the targeting potential to DCs, which has to be taken into consideration for designing novel formulations [79].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [79] source
Not checked in the free run.
- Premisecitation
WGA specifically binds to N-acetyl-d-glucosamine and sialic acid moieties on epithelial cells and M cells.
“WGA specifically binds to N-acetyl-d-glucosamine and sialic acid moieties of both, epithelial cells and M cells [106,107].”
Quote in the paperSubstantial claim0 of 2 sources checked - Interpretationcitation
Results from experimental animal models can only be extrapolated to humans with limitations due to low M cell numbers and inter-species variability in surface receptors.
“Due to the low number of M cells in the intestinal tract and due to the inter-species variability in surface receptors [99], results obtained in experimental animal models can only be extrapolated into the human situation when taking into account certain limitation.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [99] source
Not checked in the free run.
- Premisecitation
Insulin absorption was markedly enhanced by an insulin-soybean phosphatidyl choline complex loaded into PLGA NPs compared with subcutaneous insulin injection.
“Thus, the insulin absorption was markedly enhanced by the use of an insulin–soybean phosphatidyl choline complex loaded into PLGA NPs compared with subcutaneous insulin injection [73].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [73] source
Not checked in the free run.
- Premisecitation
It is questionable whether serum antibody titers are significant for protection against rotaviruses because mucosal IgA protection is most efficient.
“However, it is questionable whether antibody titers in serum are significant for protection against rotaviruses as it is well known that mucosal IgA protection is most efficient [80].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [80] source
Not checked in the free run.
- Premisecitation
Oral immunization with LTA-coated HBsAg PLGA NPs elicited significantly higher sIgA response than uncoated nanospheres.
“Upon oral immunization these particle carriers elicited a significantly higher sIgA response compared with uncoated nanospheres.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [114] source
Not checked in the free run.
- Premisecitation
Oral application of OVA-loaded PLGA nanospheres coated with PEG initiated a high OVA-specific IgG response at very low allergen amounts (5 μg).
“Oral application of OVA-loaded PLGA nanospheres, which were further coated with PEG to reduce particle aggregation and to enhance particulate blood circulation [78], initiated a high OVA-specific IgG response at very low allergen amounts (5 μg).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [78] source
Not checked in the free run.
- Premisecitation
In a DMBA-induced breast cancer rat model, oral doxorubicin-loaded PLGA NPs had higher antitumor efficacy due to enhanced bioavailability, tumor permeation, and retention.
“in a 7,12-dimethylbenz[a]anthracene-induced breast cancer rat model, oral administration of doxorubicin loaded PLGA NPs revealed a higher antitumor efficacy as a result of enhanced bioavailability, tumor permeation and retention effect [74].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [74] source
Not checked in the free run.
- Premisecitation
UEA-I-functionalized HBsAg-incorporating NPs specifically bind via α-l-fucose to mouse M cells ex vivo.
“These NPs were shown to specifically bind via α-l-fucose to mouse M cells ex vivo.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [113] source
Not checked in the free run.
- Premisecitation
Encapsulation of tamoxifen or doxorubicin in particles significantly increased their bioavailability.
“It was reported that the bioavailability of chemotherapeutic drugs, such as tamoxifen or doxorubicin, encapsulated in particles significantly increased [83–84].”
Quote in the paperNot a substantial claim0 of 2 sources checked - Premisecitation
Bacterial and viral transcytosis via M cells may in some cases be initiated by a receptor-mediated process.
“Using this model, it has become obvious that bacterial and viral transcytosis via M cells might, in some cases, be initiated by a receptor-mediated process [99].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [99] source
Not checked in the free run.
- Premisenone given
Most studies focused on PLGA particle carriers loaded with drugs or antigen without further functionalization of the particle surface for cell targeting in the GI tract.
“The majority of these studies focused on the investigation of PLGA particle carriers loaded with drugs or antigen but without further functionalization of the particle surface for cell targeting in the GI tract.”
Quote in the paperNot a substantial claim - Premisecitation
In mice, three oral immunizations with UEA-I-coated HBsAg-loaded NPs plus booster after 3 weeks induced HBsAg-specific serum antibody titers comparable to intramuscular HBsAg/alum.
“After three oral immunizations with UEA-I coated, HBsAg loaded NPs and a booster immunization after 3 weeks, mice developed HBsAg-specific serum antibody titers comparable to levels measured after intramuscular injection of HBsAg adsorbed to aluminum hydroxide.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [113] source
Not checked in the free run.
- Premisecitation
LTA targets M cells specifically via α-l-fucose.
“Similar to UEA-I, LTA targets M cells specifically via α-l-fucose.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [114] source
Not checked in the free run.
- Premisecitation
PLGA microspheres showed an improved antibody response when applied via the intranasal route.
“PLGA microspheres showed an improved antibody response when being applied via the intranasal route.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [58] source
Not checked in the free run.
- Premisecitation
Pathogens are suspected to use specific binding to M cell surface structures to invade the human body via transmucosal transport.
“it is suspected that pathogens use specific binding approaches to surface structures on M cells to invade the human body via transmucosal transport [99].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [99] source
Not checked in the free run.
- Premisecitation
Claudin 4 functions as a receptor for CPE.
“The latter functions as a receptor for Clostridium perfringens enterotoxin (CPE) and has been recent focus for targeting approaches [101].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [101] source
Not checked in the free run.
- Premisecitation
In a cited study, two oral administrations of H. pylori-PLGA nanospheres significantly elevated H. pylori-specific serum IgG1, IgG2b, and gut lavaged IgA.
“Kim et al. demonstrated that after two oral administrations of H. pylori-PLGA nanospheres, H. plyori-specific serum IgG1 and IgG2b levels and gut lavaged IgA were significantly elevated [81].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [81] source
Not checked in the free run.
- Premisecitation
HBsAg encapsulated in LTA-coated PLGA NPs can be effectively delivered to murine M cells.
“Encapsulation of HBsAg in LTA-coated PLGA NPs can effectively be delivered to murine M cells.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [114] source
Not checked in the free run.
- Premisecitation
A single administration of PLA and PLGA microspheres containing rotavirus elicited an increase in systemic rotavirus-specific IgA and IgG antibody titers in mice.
“A single particle administration elicited an increase of systemic rotavirus-specific IgA and IgG antibody titers.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [58] source
Not checked in the free run.
- Premisecitation
Encapsulation of the food allergen OVA, which is degraded under physiological conditions during GI transit, remained stable when entrapped within PLGA NPs.
“In this study, encapsulation of the food allergen OVA, which was found to be degraded under physiological conditions during the GI transit [77], remained stable when entrapped within PLGA NPs.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [77] source
Not checked in the free run.
- Interpretationreasoning
Lack of data on specific receptors on human M cells may make development of M-cell-specific targeting strategies more difficult than expected.
“As data on the expression of specific receptors on human M cells is lacking, the development of M-cell-specific targeting strategies, such as the coating of particles with lectins or lectin mimetics [117,119], might be more difficult than expected.”
Quote in the paperSubstantial claim0 of 2 sources checked - Premisecitation
PLGA particles co-encapsulated with CpG, protamine, and bee venom phospholipase A2 counterbalanced Th2 responses.
“recent data indicated the counterbalance of Th2 responses by the use of PLGA particles co-encapsulated with the immuno stimulatory TLR9 ligand oligodeoxy-nucleotide (CpG), protamine and phospholipase A2 from bee venom [123].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [123] source
Not checked in the free run.
- Interpretationcitation
AAL-functionalized MPs are a potential novel strategy for oral immunotherapy against Th2-biased diseases like allergy.
“These studies corroborate the potential of AAL functionalized MPs as a novel strategy for oral immunotherapy against Th2-biased diseases, such as allergy.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [75] source
Not checked in the free run.
- Premisecitation
Oral immunization with TGDK-conjugated multi antigens containing BSA and rhesus CCR5-derived cyclopeptide elicited mucosal rcDDR5-specific IgA with neutralizing activity.
“oral immunization with TGDK-conjugated multi antigens containing bovine serum albumin and a rhesus CCR5-derived cyclopeptide, which has recently been discussed as an attractive target for mucosal HIV-1 vaccines, elicited mucosal rcDDR5-specific IgA with neutralizing activity.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [119] source
Not checked in the free run.
- Premisecitation
AAL-coated PLGA microspheres induced high IL-2 and IFN-γ and low IL-5 and IL-10 in PBMCs of allergic individuals.
“AAL-coated PLGA microspheres induced a high production of the Th1 cytokines IL-2 and IFN-γ compared with only small quantities of IL-5 and IL-10 in peripheral blood mononuclear cells of allergic individuals.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [115] source
Not checked in the free run.
- Interpretationreasoning
Micrometer-range particles are most suitable for encapsulating large proteins for allergen-specific immunotherapy because MPs have greater volume and loading capacity than NPs.
“Since the volume and, therefore, the loading capacity of MPs by far exceeds that of NPs, the usage of particles in the micrometer range seems to be most suitable in the case of encapsulating large proteins for allergen-specific immunotherapy.”
Quote in the paperSubstantial claim- Rests on an assumption: Particles below 1 μm are optimally taken up by Peyer's patches and can lead to sufficient antigen processing.
- Premisecitation
Higher levels of IFN-γ and IL-2 suggested induction of cell-mediated immunity.
“This was underlined by higher levels of the Th1 cytokines IFN-γ and IL-2, suggesting the induction of cell-mediated immunity [114].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [114] source
Not checked in the free run.
- Premisecitation
After gavage of TGDK to rhesus macaques, the dendrimer was efficiently delivered to rhesus Peyer's patches' M cells in vivo.
“After gavage of TGDK to rhesus macaques, the dendrimer was efficiently delivered to rhesus Peyer’s patches’ M cells in vivo.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [119] source
Not checked in the free run.
- Premisecitation
Spleen cells from animals treated orally with AAL MPs secreted significantly more IL-10 and IFN-γ.
“spleen cells of animals being treated with AAL MPs via the oral route secreted significantly more T-regulatory cytokine IL-10 and Th1 cytokine IFN-γ [75].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [75] source
Not checked in the free run.
- Premisecitation
Murine system mirrors only partially human situation.
“the murine system mirrors only partially the situation in human patients [129].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [129] source
Not checked in the free run.
- Premisecitation
Recombinant lectins with modified properties but same binding characteristics have been described for recombinant mistletoe lectin.
“The production of recombinant lectins with modified properties but with the same binding characteristics has been described for the recombinant mistletoe lectin [118].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [118] source
Not checked in the free run.
- Premisecitation
In naive BALB/c mice, six oral immunizations with AAL-coated birch-pollen-loaded PLGA MPs induced three-times higher IgG2a antibody response than noncoated MPs.
“Naive BALB/c mice were orally immunized with AAL-coated, birch-pollen-loaded MPs six-times. This oral immunization regimen induced a three-times higher IgG2a antibody response compared with noncoated MPs [116].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [116] source
Not checked in the free run.
- Premisecitation
AAL coating of fluospheres increased transcytosis of MPs by M cells compared with plain particles.
“AAL coating of fluospheres resulted in an increased transcytosis of MPs by M cells compared with plain particles [115].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [115] source
Not checked in the free run.
- Premisecitation
AAL binds to human M cells in an in vitro M cell-like co-culture model.
“a common in vitro M cell-like co-culture model of human origin was used to confirm AAL binding to human M cells.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [115] source
Not checked in the free run.
- Premisecitation
The M cell-like co-culture model is based on colon cancer cell line that differently expresses carbohydrate residues.
“The only valuable model currently available, the M cell-like co-culture model, is based on the formation of M cells from the colon cancer cell line, which is known to differently express carbohydrate residues [24].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [24] source
Not checked in the free run.
- Interpretationcitation
AAL-coated microspheres are suitable for allergy therapy.
“These data supported the suitability of AAL-coated microspheres for allergy therapy.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [115] source
Not checked in the free run.
- May combine two claims. 70
- Classified as probably not a substantial claim. 19
May combine two claims.
PremisecitationPLGA and PLA are highly biocompatible and biodegradable, their degradation products are eliminated via the Krebs cycle, and their use in human patients has been approved by the US FDA.
“Both PLGA and PLA are characterized by high biocompatibility and biodegradability, as their degradation products are eliminated via the Krebs cycle, which is why their application in human patients has been approved by the US FDA [3–5].”
Quote in the paperNot a substantial claim0 of 3 sources checkedMay combine two claims.
PremisecitationThe harsh conditions in the gastrointestinal tract make oral immunotherapeutic drugs difficult to design and often lead to low bioavailability.
“However, the harsh conditions of the gastrointestinal (GI) environment constitute a substantial challenge for designing immunotherapeutic drugs, which often suffer from low bioavailability when administered via the oral route.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [22] source
Not checked in the free run.
May combine two claims.
PremisecitationThe w/o/w method is relatively simple and economic, but it can have low encapsulation efficiency or payload and a large initial burst release because organic solvent removal is slow.
“Although this w/o/w method is a relatively simple and economic technique [9], the sometimes low encapsulation efficiency or payload as well as the huge initial burst release, because of the limited speed of removal of organic solvent, are disadvantageous [10].”
Quote in the paperNot a substantial claim0 of 2 sources checkedProbably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationThe solid-in-oil-in-water method may be useful for entrapping unstable antigens because the solid state favors protein stability and bioactivity.
“Since the solid state is most favorable for protein stability and, thus, bioactivity, this technique might be useful for entrapment of unstable antigens [11].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [11] source
Not checked in the free run.
May combine two claims.
PremisereasoningEncapsulating therapeutic agents in polymer particles in the nano- or micrometer range is a novel approach that improves oral application and bioavailability.
“During recent years, one of these novel approaches has been the encapsulation of therapeutic agents into polymer particles within the nano- or micro-meter range in size.”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationParticle size is pivotal for stability, distribution, release of encapsulated antigens, and induction of immune responses.
“The particles’ size is pivotal for stability, distribution, release of the encapsulated antigens and induction of immune responses [36,37].”
Quote in the paperSubstantial claim0 of 2 sources checkedMay combine two claims.
PremisecitationNPs are rapidly internalized mainly by receptor-mediated endocytosis and then disseminated systemically.
“NPs are rapidly internalized mainly by a process that involves receptor-mediated endocytosis, and are then disseminated systemically [5,38].”
Quote in the paperSubstantial claim0 of 2 sources checkedMay combine two claims.
Premisenone givenMPs and NPs have properties that make them suitable for oral use and that raise the bioavailability of encapsulated substances.
“These micro particles (MPs) or nanoparticles (NPs) display several features, which make them suitable for oral application and increase bioavailability of encapsulated substances.”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationM cells have reduced digestive function because they lack brush-border enzymes such as alkaline phosphatase, which makes them interesting for drug targeting.
“With the loss of brush-border enzymes, such as alkaline phosphatase, M cells show a reduced digestive function, which makes them even more interesting for drug targeting [26,27].”
Quote in the paperSubstantial claim0 of 2 sources checkedProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
PremisecitationM cells are part of the follicle-associated epithelium overlying organized gut-associated lymphoid tissue, which can be isolated or in Peyer's patches.
“M cells are part of the follicle-associated epithelium overlying the organized gut-associated lymphoid tissue, which can either be located in isolated form or within organized follicular clusters, the so-called Peyer’s patches [24,25].”
Quote in the paperNot a substantial claim0 of 2 sources checkedProbably not a substantial claim: may not pass S3 (load-bearing).
Premisenone givenThe double-emulsion technique and spray-drying technique are typically applied today to prepare vaccine-loaded particles.
“It has become apparent that two techniques, the double-emulsion technique and spray-drying technique, are typically being applied today.”
Quote in the paperNot a substantial claimMay combine two claims.
InterpretationreasoningM cells transport foreign material intact from the gut lumen to mucosa-associated lymphatic tissue, making them an optimal entry for antigens in oral immunotherapy.
“These cells are responsible for antigen-specific intestinal immune responses by transporting foreign material from the gut lumen to the mucosa-associated lymphatic tissue in an intact form, making them an optimal entry for antigens in oral immunotherapy.”
Quote in the paperSubstantial claim0 of 3 sources checkedMay combine two claims.
PremisecitationIn Caco-2 in vitro studies, 100-nm NPs showed high interaction rates (more than 6000 PLGA and 200,000 polystyrene particles per cell), while 1- or 2-μm particles interacted in very low numbers (12 and below).
“NPs of 100-nm size showed a high interaction rate of more than 6000 PLGA and 200,000 polystyrene (PS) particles per Caco-2 cell. Particles with a size of 1 or 2 μm interacted in very low numbers (12 and below) with one Caco-2 cell [41].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [41] source
Not checked in the free run.
May combine two claims.
PremisecitationAfter binding to the apical side of M cells, macromolecules are endocytosed via clathrin-coated vesicles, reach the lysosomal compartment, and are exocytosed basolaterally to be taken up by APCs.
“Once bound to the apical side of M cells, macromolecules are endocytosed via clathrin-coated vesicles, thereby reaching the lysosomal compartment, from which they are exocytosed to the basolateral site to be taken up by antigen presenting cells (APCs) [34,35].”
Quote in the paperNot a substantial claim0 of 2 sources checkedProbably not a substantial claim: may not pass S3 (load-bearing).
Premisenone givenThe w/o/w double-emulsion technique permits entrapment of hydrophilic substances such as vaccines.
“The water-in-oil-in-water (w/o/w) or double-emulsion technique allows for entrapment of hydrophilic substances such as vaccines.”
Quote in the paperNot a substantial claimMay combine two claims.
PremisecitationParticles of 150 nm have prolonged circulation time and sustained blood levels compared with particles below 100 nm or above 200 nm, which may be taken up by reticulo-endothelial system cells; NPs between 100 and 200 nm can escape reticulo-endothelial system uptake.
“Particles with a size of 150 nm show a prolonged circulation time and sustained blood levels compared with particles with a size lower than 100 nm or above 200 nm, which may be taken up by the reticulo-endothelial system cells. In comparison, NPs between 100 and 200 nm can escape reticulo-endothelial system uptake [5,43].”
Quote in the paperNot a substantial claim0 of 2 sources checkedMay combine two claims.
PremisecitationWhen NPs shuttle through intestinal epithelial cells, encapsulated drugs avoid P-glycoprotein efflux from enterocytes and bypass liver metabolism, which increases oral bioavailability.
“Upon shuttling of NPs through intestinal epithelial cells encapsulated drugs circumvent the P-glycoprotein efflux from enterocytes and bypass liver metabolism, which enhance their oral bioavailability [42].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [42] source
Not checked in the free run.
May combine two claims.
Premisenone givenFunctionalizing particles with targeting substances can direct their binding to specific cells and increase their uptake by intestinal cells.
“Furthermore, functionalization of particles by special targeting substances can direct particle binding to specific cells and enhance the particle uptake capacity via intestinal cells.”
Quote in the paperNot a substantial claimMay combine two claims.
PremisecitationThe proportion of M cells in follicle-associated epithelium of Peyer's patches can be high in rabbits and mini-pigs, but is much lower in rodents (10%) and humans (<5%).
“Although the proportion of M cells in follicle-associated epithelium of Peyer’s patches can be high in rabbits and mini-pigs, the occurrence in rodents (10%) and humans (<5%) is much lower [29].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [29] source
Not checked in the free run.
May combine two claims.
PremisecitationOral immunotherapy is preferred over parenteral administration because patients comply better and complications occur less often.
“Although immunotherapy is often applied parenterally, the oral administration route is preferred due to higher compliance of patients and lower complication rates [1].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [1] source
Not checked in the free run.
May combine two claims.
PremisecitationSmall NPs were detected intracellularly, including within nuclei, whereas particles larger than 300 nm attached to the apical membrane of Caco-2 cells.
“Furthermore, while small NPs were detected intracellularly, also within the nuclei, particles bigger than 300 nm were attached to the apical membrane of Caco-2 cells.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [41] source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationSeveral new methods for manufacturing PLGA or PLA particles have been reported, including ultrasonic atomization, electrospray, microfluidic, pore-closing/thermoreversible-gel, and microfabrication.
“Recently, several new methods to manufacture PLGA or PLA particles have been reported, such as the ultrasonic atomization method [14,15], the electrospray method [16], the microfluidic method [17,18], the pore-closing and thermoreversible-gel method [19,20], and the microfabrication method [21].”
Quote in the paperNot a substantial claim0 of 5 sources checkedMay combine two claims.
PremisecitationEncapsulation of antigens in particle carriers protects them from harsh GI degrading conditions, allows intestinal uptake of intact antigens and drugs, and avoids hepatic first-pass metabolism because the particle matrix protects the payload.
“Encapsulation of antigens into particle carriers protects against these harsh GI degrading conditions [23], enabling an intestinal uptake of intact antigens and drugs, and the circumvention of the hepatic first-pass metabolism due to protection of the payload by the particle matrix.”
Quote in the paperSubstantial claim0 of 2 sources checkedMay combine two claims.
PremisecitationTranscytosis through the intestinal epithelial layer depends on particle size, with below 1 μm optimal for M-cell absorption, and also on particle charge and hydrophilicity.
“The capacity of transcytosis through the intestinal epithelial layer depends on the size, with a particle size of below 1 μm for optimal M-cell absorption [30], but also on the charge and hydrophilicity of the particle carrier [31–33].”
Quote in the paperSubstantial claim0 of 4 sources checkedProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
PremisecitationSpray-drying allows easy tuning of particle characteristics and scale-up, but high product loss, especially in small batches, may be crucial.
“This technique allows easy tuning of particle characteristics and scale-up, but high product loss, especially in small batches, might be crucial [13].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [13] source
Not checked in the free run.
May combine two claims.
PremisecitationPeptides loaded into NPs targeting DC-SIGN were found in the lysosomal compartment of DCs within 24 h and were presented to T cells despite the presence of fluorescent labels.
“In this study, peptides loaded into NPs, which specifically targeted DC-SIGN on DCs, were found in the lysosomal compartment of DCs within 24 h and were presented to T cells despite the presence of fluorescent labels [68].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [68] source
Not checked in the free run.
May combine two claims.
PremisecitationMannan or PEG coating protects against protein opsonization, enabling specific receptor-ligand binding.
“Mannan or PEG coating was shown to protect against protein opsonization, enabling specific receptor-ligand binding.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [72] source
Not checked in the free run.
May combine two claims.
PremisecitationNPs surface modification with an antibody against the DC lectin DEC-205 receptor induced IL-10 production by DCs and T cells in vitro; intraperitoneal injection into OVA-primed mice produced a similar IL-10 pattern dependent on the density of surface modification.
“Recently, NPs’ surface modification with an antibody against the DC lectin DEC-205 receptor induced the production of IL-10 by DCs and T cells in vitro. When these modified particles were intraperitoneally injected into ovalbumin (OVA) primed mice, a similar IL-10 pattern was observed, which was dependent on the density of surface modification [69].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [69] source
Not checked in the free run.
May combine two claims.
PremisecitationSurface modification with poloxamer or particle preparation with different polymers influences particle surface charge, which could contribute to reduced intestinal uptake.
“However, surface modification with poloxamer or particle preparation with different polymers influences the surface charge of the particles, which could contribute to reduced intestinal uptake [49].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [49] source
Not checked in the free run.
May combine two claims.
PremisecitationMannosylated particles can specifically deliver antigens and drugs to DCs and enhance presentation to T cells.
“Previous studies have shown that mannosylated particles can specifically deliver antigens and drugs to DCs and result in enhanced presentation to T cells [70].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [70] source
Not checked in the free run.
May combine two claims.
PremisecitationParticle structures smaller than 5 μm are taken up by APCs such as dendritic cells and macrophages and transported directly to the lymph node, where encapsulated antigen can be presented to T cells.
“Particle structures smaller than 5 μm are taken up by APCs, such as dendritic cells (DCs) and macrophages [59–61], and are transported directly to the lymph node [58], where the encapsulated antigen can be presented to T cells.”
Quote in the paperSubstantial claim0 of 4 sources checkedClassified as probably not a substantial claim. May combine two claims.
PremisecitationPLGA affects the immune response through adjuvant properties, which were hypothesized to result from the particulate structure of the allergen carrier and sustained allergen release from particles.
“PLGA is not only a highly biocompatible and bio degradable material, it further affects the immune response via its adjuvant properties [50], which were hypothesized to be due to the particulate structure of the allergen carrier and due to the sustained allergen release from the particles [51].”
Quote in the paperSubstantial claim0 of 2 sources checkedMay combine two claims.
PremisecitationEncapsulated antigen is slowly and continuously released into the cell, leading to enhanced antibody responses, increased IL-4 production, and MHC-II upregulation, which together trigger a predominant humoral response.
“Additionally, the encapsulated antigen is slowly and continuously released into the cell leading to enhanced antibody responses, increased production of IL-4 and upregulation of MHC-II molecules, which in concert triggers a predominant humoral response.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [2] source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationThe impact of particle hydrophilicity on intestinal uptake has been described controversially in the literature.
“The impact of particle hydrophilicity on intestinal uptake has been described very controversially in literature.”
Quote in the paperNot a substantial claim0 of 3 sources checkedMay combine two claims.
PremisecitationThe capacity of PLGA particles to act as a vaccine adjuvant is high and comparable to conventional aluminum-adsorbed vaccine formulations.
“Various studies demonstrated that the capacity of PLGA particles to act as vaccine adjuvant was high and comparable to the conventional aluminum-adsorbed vaccine formulations [52–54].”
Quote in the paperSubstantial claim0 of 3 sources checkedMay combine two claims.
PremisecitationPositively charging PLGA particles, for example with positively charged stabilizers, increases epithelial penetration and systemic uptake of encapsulated slightly soluble drugs; these favorable characteristics are not found with anionic stabilizers.
“However, positively charging PLGA particles, for example using positively charged stabilizers, increases the epithelial penetration and systemic uptake of encapsulated, slightly soluble drugs. These favorable characteristics are not found in particulate carriers prepared with anionic stabilizers [5,46].”
Quote in the paperNot a substantial claim0 of 2 sources checkedMay combine two claims.
PremisecitationA high concentration of released soluble antigen leads to direct binding of antigen to MHC-II molecules and subsequent presentation.
“The high concentration of released soluble antigen leads to direct binding of the antigen to MHC-II molecules and subsequent presentation [2].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [2] source
Not checked in the free run.
May combine two claims.
PremisecitationGaumet et al. reported that coating PLGA particles with chitosan, which did not affect surface charge or particle size, enhanced interaction with intestinal Caco-2 cells.
“A recent study by Gaumet et al. reported that modification of surface hydrophilicity by coating PLGA particles with chitosan, which did not affect surface charge or particle size, enhanced the interaction of particles with intestinal Caco-2 cells [49].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [49] source
Not checked in the free run.
May combine two claims.
PremisecitationContinuous release of inoculated antigens from PLGA particles after the first burst is advantageous for restimulating memory cells and is responsible for long protection even after one vaccination.
“The continuous release of inoculated antigens from PLGA particles after the first burst is advantageous to restimulate memory cells and responsible for a long protection time even after one vaccination [52], underlining the beneficial effects of PLGA as a carrier substance for novel vaccination approaches.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [52]
Not checked in the free run.
May combine two claims.
PremisecitationMannose coupling to microspheres initiated phagocytosis by C-type lectin receptor but could not stimulate DC maturation and activation toward T-cell responses.
“However, mannose coupling to microspheres initiated the phagocytosis by C-type lectin receptor, it could not stimulate DC maturation and activation toward T-cell responses [72].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [72] source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationOral immunomodulation with polymeric particulate carriers has been investigated for immunosuppressive drugs, viral and bacterial antigens, hormones, anticancer drugs, and allergens.
“Oral immunomodulation with polymeric particulate carriers has been investigated for a wide range of therapeutic applications, such as immuno suppressive drugs [42], viral and bacterial antigens [58,65], hormones [5,73], anticancer drugs [74], and allergens [75].”
Quote in the paperNot a substantial claim0 of 5 sources checkedMay combine two claims.
PremisecitationHydrophobicity of polymer microspheres and a rough surface increase attachment to APC surfaces and enhance antibody response.
“the hydrophobicity of polymer microspheres and a rough surface further increase the attachment to the surface of APCs [65], and enhance the antibody response [66].”
Quote in the paperSubstantial claim0 of 2 sources checkedMay combine two claims.
PremisecitationParticle size determines the immune response outcome: MPs between 1 and 10 μm promote humoral responses, while NPs below 1 μm mainly induce cellular responses.
“Only MPs between 1 and 10 μm in size promote humoral responses, whereas NPs below 1 μm mainly induce cellular responses (Figure 1) [58].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [58] source
Not checked in the free run.
May combine two claims.
PremisecitationNPs loaded with FITC-bovine serum albumin were phagocytosed by APCs, causing a two- to threefold increase in cell size, and were continuously endocytosed and exocytosed; only low concentrations of intracellularly released antigen were observed over time.
“NPs loaded with FITC–bovine serum albumin were shown to be phagocytosed by APCs, leading to a two–threefold increase of cell size, and were then continuously endocytosed and exocytosed from the cells. Thus, only low concentrations of intra cellularly released antigen could be observed over time [2].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [2] source
Not checked in the free run.
May combine two claims.
InterpretationreasoningIntestinal epithelial transport of nanometer-range particles might be optimal, but nanospheres are taken up with distinct intracellular distribution, which might lead to unknown side effects.
“While the intestinal epithelial transport of particles in the nanometer range might be optimal, one has to keep in mind that nanospheres are taken up into the cells with distinct intracellular distribution, which might lead to side effects not yet known.”
Quote in the paperNot a substantial claimMay combine two claims.
PremisereasoningImmunizations with NPs containing hepatitis B surface antigen led to low IgG production, IFN-γ secretion, and MHC-I upregulation on APCs, indicating induction of a cellular immune response.
“Interestingly, immunizations with NPs containing hepatitis B surface antigen (HBsAg) led to low production of IgG, secretion of IFN-γ and upregulation of MHC-I on APCs, which indicated the induction of a cellular immune response.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
PremisecitationWGA is a dietary nontoxic lectin contained in wheat flour.
“WGA represents a dietary nontoxic lectin, which is contained in wheat flour [22].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [22] source
Not checked in the free run.
May combine two claims.
PremisecitationGavages of UEA-I-coated NPs induced mucosal sIgA secretion and IL-2 and IFN-γ production in spleens, indicating Th1-dominant immune response.
“Furthermore, gavages of these UEA-I coated NPs-induced mucosal secretion of sIgA and the production of IL-2 and IFN-γ in spleens, indicating a Th1-dominant immune response [113].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [113] source
Not checked in the free run.
May combine two claims.
PremisecitationIn diabetic rats, PLGA NPs loaded with insulin showed slower absorption and sustained elimination, while serum insulin concentration steadily increased over 6 h.
“In a recent study, PLGA NPs loaded with insulin for oral application in diabetic rats revealed slower absorption and sustained elimination, while serum insulin concentration steadily increased over 6 h.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [73] source
Not checked in the free run.
May combine two claims.
PremisecitationEpithelial glycosylation patterns in the gut are altered in colon cancer, questioning the value of the M-cell-like co-culture model.
“As this model is based on the use of carcinoma cell lines, it should be noted that epithelial glycosylation patterns in the gut are altered in colon cancer, questioning the value of this experimental model [24].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [24] source
Not checked in the free run.
May combine two claims.
PremisecitationLectins selectively bind to carbohydrate residues of epithelial cell glycocalyx and can be used on particle surfaces to target M cells.
“Lectins are proteins that selectively bind to carbohydrate residues of epithelial cells’ glycocalyx and may serve as molecules on particle surface for specifically targeting M cells [103,104].”
Quote in the paperSubstantial claim0 of 2 sources checkedMay combine two claims.
PremisecitationPossible M-cell interaction partners include TLR4, platelet activating factor receptor, α5β1 integrin, carbohydrates, and Claudin 4.
“Possible interaction partners might be M-cell expressed TLR4, platelet activating factor receptor and α5β1 integrin [100], carbohydrates and Claudin 4.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [100] source
Not checked in the free run.
May combine two claims.
PremisecitationConcanavalin A interacts with intestinal epithelium and immune cells like macrophages, activating them and upregulating TLRs and production of NO and proinflammatory cytokines.
“Concanavalin A can not only interact with the intestinal epithelium but also with immune cells, such as macrophages, resulting in their activation and subsequent upregulation of TLRs as well as the production of NO and proinflammatory cytokines [110–112].”
Quote in the paperSubstantial claim0 of 3 sources checkedMay combine two claims.
PremisecitationEncapsulation of antigens into PLGA particles both protects from GI digestion and initiates specific immune responses through IgG and IFN-γ production at very low antigen amounts.
“Recently, it was observed that the encapsulation of antigens into PLGA particles did not only protect from GI digestion, but also initiated specific immune responses by the means of IgG and IFN-γ production at very low antigen amounts [76].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [76] source
Not checked in the free run.
May combine two claims.
PremisecitationCoating CPE30 to PLGA NPs increased uptake by upper airways after intranasal administration and by intestinal M cells after ingestion.
“CPE30, the C-terminal 30 amino acid part of CPE, was coated to PLGA NPs, which increased the uptake by upper airways when administered intranasally or by intestinal M cells after ingestion [101].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [101] source
Not checked in the free run.
May combine two claims.
PremisecitationEnterocyte-specific targeting (e.g., by WGA) substantially increases transepithelial transport and induces a systemic IgG-mediated immune response.
“Enterocyte-specific targeting, for example by WGA, substantially increases the transepithelial transport, which may especially be of interest for drug development where no mucosal immune response induction is needed. Enterocyte-specific targeting induces a rather systemic IgG-mediated immune response [22].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [22] source
Not checked in the free run.
- Rests on an assumption: Enterocytes represent the majority of epithelial cells in the intestinal tract.
May combine two claims.
PremisecitationVery low IL-4 and significantly higher IFN-γ production by spleen cells was observed in animals immunized with particles compared with mice fed unprotected OVA, and this was more pronounced when β1 integrin on M cells was targeted by an RGD-containing peptide.
“Moreover, very low IL-4 and significantly higher IFN-γ production of spleen cells was observed in animals immunized with particles compared with mice being fed unprotected OVA, which was even more pronounced when the β1 integrin on M cells was specifically targeted by an RGD-containing peptide [76].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [76] source
Not checked in the free run.
May combine two claims.
PremisereasoningDevelopment of PLGA formulations is complicated when hydrophilic drugs such as insulin are encapsulated, and this problem can be solved by specific ampholytic surfactants such as phospholipids.
“However, the development of these formulations becomes even more complicated when hydrophilic drugs, such as insulin, are subject to encapsulation. This problem can be solved by the use of specific ampholytic surfactants, such as phospholipids.”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationWGA attached to carbopol used for surface modification of liposomes significantly increased receptor-mediated binding to Caco-2 cells and enhanced pharmacological efficacy of calcitonin loaded into nanocarriers.
“WGA attached to carbopol has recently been used for surface modification of liposomes, which significantly increased the receptor mediated binding to Caco-2 cells and further enhanced the pharmaco logical efficacy of calcitonin, when loaded into the nanocarriers [109].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [109] source
Not checked in the free run.
May combine two claims.
InterpretationreasoningFunctionalization of PLGA particle surface with bioactive substances targets mucosal cells, improving cellular uptake and transepithelial transport and inducing systemic and mucosal immune responses.
“Following this approach, mucosal cells are specifically targeted, thereby improving the cellular uptake as well as transepithelial transport and inducing not only a systemic, but also a strong mucosal immune response.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
PremisecitationDistribution of surface structures on human M cells may differ across intestinal regions, indicating local functionality.
“it has to be kept in mind that the distribution of surface structures on human M cells of different intestinal regions may also differ [24], which may indicate a certain local functionality.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [24] source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Interpretationnone givenUEA-I originates from a highly toxic plant, making its beneficial application in humans questionable.
“Although UEA-I may be a promising targeting substance, its origin is a highly toxic plant, which makes its beneficial application in humans questionable.”
Quote in the paperNot a substantial claimMay combine two claims.
PremisecitationOrally applied PLA microspheres induced a more persistent and longer-lasting serum IgA antibody response, which could be explained by higher hydrophobicity of PLA and slower polymer degradation.
“Orally applied PLA microspheres induced a more persistent and longer-lasting serum IgA antibody response, which could be explained by the higher hydro phobicity of PLA and the slower polymer degradation.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [58] source
Not checked in the free run.
May combine two claims.
InterpretationreasoningM-cell-specific targeting may increase efficiency of oral particle carriers in Th2 modulation because transcytosed particles reach lymphatic tissue and induce strong mucosal and systemic immune responses.
“As targeting of orally applied particle carriers to epithelial cells in situations of Th2 modulation does not seem sufficient to trigger immune responses, a M-cell-specific targeting approach may increase the efficiency, because transcytosed particles reach the lymphatic tissue underlying the M cells and induce a strong mucosal, as well as systemic immune response.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S4 (based).
InterpretationreasoningLectins that bind specifically to α-l-fucose should result in M-cell-specific adherence when used as targeting moieties.
“As the lectins listed below bind specifically to α-l-fucose, their use as targeting moieties should result in M-cell-specific adherence.”
Quote in the paperNot a substantial claimMay combine two claims.
InterpretationcitationSubstantial differences in M-cell distribution and surface receptor expression between mice and men mean animal study data might not reflect human situation.
“Due to substantial differences of M-cell distribution and surface receptor expression between mice and men [99], data generated in animal studies might not reflect the situation in humans.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [99] source
Not checked in the free run.
Classified as probably not a substantial claim. May combine two claims.
PremisecitationM cells account for only a minority in intestinal epithelium and might exert diverse functions in different intestinal regions.
“these cells account for only a minority in the intestinal epithelium and might exert diverse functions in different intestinal regions [24]”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [24] source
Not checked in the free run.
May combine two claims.
PremisecitationAAL possesses α-l-fucose specificity and binds to murine Peyer's patches.
“AAL from the edible, nontoxic orange peel mushroom Aleuria aurantia also possesses α-l-fucose specificity and, thus, was shown to bind to murine Peyer’s patches [115].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [115] source
Not checked in the free run.
May combine two claims.
PremisecitationWGA and AAL are nontoxic and highly resistant to gastric digestion, and enhance retention time and transepithelial transport of MPs at GI mucosa, improving efficacy.
“The targeting substances WGA [120] and AAL are nontoxic and highly resistant against gastric digestion [Diesner SC, Schultz C, Wang X-Y et al., Unpublished Data] and enhance the retention time and transepithelial transport of MPs at the GI mucosa, finally resulting in improved efficacy, as reviewed by Des Rieux et al. [23].”
Quote in the paperSubstantial claim0 of 2 sources checkedMay combine two claims.
Interpretationnone givenClinical trials in human patients proving usability of PLGA particles for oral immunotherapy are still missing, making conclusions on efficacy and applicability impossible.
“clinical trials in human patients proving the usability of PLGA particles for oral immunotherapy application are still missing, making conclusions on their efficacy and applicability impossible.”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationIn birch pollen-sensitized mice, 15 oral treatments with AAL-functionalized allergen-loaded microspheres increased birch pollen-specific IgG2a without affecting IgE and IgG1, indicating Th1-biased immune response.
“Animals fed with AAL-functionalized, allergen-loaded microspheres for 15-times revealed an increase of birch pollen-specific IgG2a, whereas IgE and IgG1 were not affected, indicating the induction of a prominent Th1-biased immune response.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [75] source
Not checked in the free run.
Probably not a substantial claim: may not pass S2 (checkable), S4 (based).
Interpretationnone givenFunctionalized particles loaded with active agents to be delivered to GALT might represent successful novel treatment strategy, especially in Th2-biased situations like allergic diseases.
“functionalized particles loaded with active agents to be delivered to the gut-associated lymphoid tissue, might represent a successful novel treatment strategy, especially in situations when the immune system is biased towards Th2, such as allergic diseases.”
Quote in the paperNot a substantial claimMay combine two claims.
Premisecitationα-l-fucose is part of sparsely mucus-coated glycocalyx of M cells, so lectin-coated formulations can mediate binding of active substances.
“Since α-l-fucose is part of the sparsely mucus-coated glycocalyx of M cells, binding of active substances can be mediated by lectin-coated formulations.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [130] source
Not checked in the free run.
May combine two claims.
PremisecitationTLR9 expression is diverse in mice but restricted to B-cells and plasmacytoid DCs in humans, probably leading to different immunological responses.
“especially the receptor of CpG, TLR9, is diversely expressed in mice, while in humans its expression is restricted to B-cells and plasmayctoid DCs [124], probably leading to different immunological responses.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [124] source
Not checked in the free run.
Classified as probably not a substantial claim. May combine two claims.
InterpretationreasoningFor oral administration, lectins must resist GI transit, and carrier material must be nontoxic and non-immunogenic, achievable by synthetic modification or choice of WGA/AAL.
“For oral administration, however, these certain lectins have to resist the harsh conditions during GI transit. Additional properties required are nontoxicity as well as non-immunogenicity of the carrier material, which can be achieved by synthetic modification of the carriers or by the careful choice of naturally derived targeting substances, such as WGA and AAL.”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationA tetragalloyl d-lysine amide construct leads to successful delivery of coated PS particles to mouse M cells and may specifically bind via α-l-fucose.
“A tetragalloyl d-lysine amide construct, as the main compound of two UEA1 mimetics, leads to successful delivery of coated PS particles to mouse M cells and might specifically bind via α-l-fucose [117].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [117] source
Not checked in the free run.
May combine two claims.
PremisecitationLectins are often toxic and susceptible to proteolytic degradation in GI tract, rendering some inappropriate for in vivo application.
“lectins are often toxic and susceptible to proteolytic degradation in the GI tract, which renders some of them inappropriate for in vivo application [105,117].”
Quote in the paperSubstantial claim0 of 2 sources checkedProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
InterpretationreasoningCellular interaction is mediated by small units of lectin molecules, so designing neolectins with only binding domain might avoid undesired effects.
“cellular interaction is mediated by only small units of most complex structured lectin molecules. Thus, undesired effects might be avoided by designing ‘neolectins’, which represent exclusively the binding domain, by using phage display techniques for example.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Interpretationnone givenCell-binding is only the first stage of a complex journey through epithelial layer to subjacent immune cells before efficient immune response.
“cell-binding is only the first stage of a complex journey through the epithelial layer to the subjacent immune cells until an efficient immune response is elicited.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S2 (checkable).
InterpretationreasoningConclusions on applicability of lectin-functionalized PLGA particles for oral immunotherapy in humans must be drawn with great caution as long as suitable M-cell models and human clinical studies are missing.
“as long as suitable and physiological M-cell models, as well as human clinical studies are missing, conclusions on the applicability of lectin-functionalized PLGA particles for oral immunotherapy in humans have to be drawn with great caution.”
Quote in the paperNot a substantial claim
The paper relies on this without support.
Epithelial cells and mucus of the gastrointestinal tract carry a negative charge.
“As epithelial cells and mucus of the GI tract are negatively charged, the uptake of PLGA and PLA particles without surface modification may be poor.”
The paper relies on this without support.
Aluminum hydroxide triggers a Th2-driven immune response.
“In contrast, the widely used vaccine component aluminum hydroxide triggers a Th2-driven immune response.”
The paper relies on this without support.
Particles below 1 μm are optimally taken up by Peyer's patches and can lead to sufficient antigen processing.
“It is generally accepted that particles below 1 μm are optimally taken up by Peyer’s patches and can thus, lead to sufficient antigen processing.”
The paper relies on this without support.
Enterocytes represent the majority of epithelial cells in the intestinal tract.
“Enterocytes represent the majority of epithelial cells in the intestinal tract.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
PLGA particles are fully biocompatible, eliminated via the Krebs cycle, and cause no polymer-specific immune response.
“and are fully biocompatible being eliminated via the Krebs cycle with no polymer-specific immune response [2,4,5].”
From Characterization of Vibrio cholerae neuraminidase as an immunomodulator for novel formulation of oral allergy immunotherapy (2018) · cites this paper as [2]
For oral application, drugs must be digestion stable and have sufficient bioavailability by overcoming first-pass metabolism.
“For oral application, drugs have to fulfill several criteria, such as digestion stability and sufficient bioavailability by overcoming the first pass metabolism [2].”
From Characterization of Vibrio cholerae neuraminidase as an immunomodulator for novel formulation of oral allergy immunotherapy (2018) · cites this paper as [2]
Cites
Of Mice and Not Men: Differences between Mouse and Human Immunology
Mestas, J., & Hughes, C. C. W. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.5.2731 · Cited by 3,822 · see citing works
Yin Win, K., & Feng, S.-S. (2005) · Biomaterials · doi:10.1016/j.biomaterials.2004.07.050 · Cited by 1,452 · see citing works
Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach
des Rieux, A., Fievez, V., Garinot, M., Schneider, Y.-J., & Préat, V. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.08.013 · Cited by 1,305 · see citing works
Nanoparticle Uptake by the Rat Gastrointestinal Mucosa: Quantitation and Particle Size Dependency
Jani, P., Halbert, G. W., Langridge, J., & Florence, A. T. (1990) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1990.tb07033.x · Cited by 920 · see citing works
Jones, B. D., Ghori, N., & Falkow, S. (1994) · The Journal of Experimental Medicine · doi:10.1084/jem.180.1.15 · Cited by 883 · see citing works
The Mechanism of Uptake of Biodegradable Microparticles in Caco-2 Cells Is Size Dependent
Desai, M. P., Labhasetwar, V., Walter, E., Levy, R. J., & Amidon, G. L. (1997) · Pharmaceutical Research · doi:10.1023/a:1012126301290 · Cited by 858 · see citing works
Direct Fabrication and Harvesting of Monodisperse, Shape-Specific Nanobiomaterials
Rolland, J. P., Maynor, B. W., Euliss, L. E., Exner, A. E., Rothrock, G. D., & DeSimone, J. M. (2005) · Journal of the American Chemical Society · doi:10.1021/ja051977c · Cited by 849 · see citing works
Biologically erodable microspheres as potential oral drug delivery systems
Mathiowitz, E., Jacob, J. S., Jong, Y. S., Carino, G. P., Chickering, D. E., Chaturvedi, P., Santos, C. A., Vijayaraghavan, K., Montgomery, S., Bassett, M., et al. (1997) · Nature · doi:10.1038/386410a0 · Cited by 823 · see citing works
Synthesis and characterization of PLGA nanoparticles
Astete, C. E., & Sabliov, C. M. (2006) · Journal of Biomaterials Science Polymer Edition · doi:10.1163/156856206775997322 · Cited by 782 · see citing works
PLGA Nanoparticles in Drug Delivery: The State of the Art;
Bala, I., Hariharan, S., & Kumar, M. R. (2004) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v21.i5.20 · Cited by 739 · see citing works
Transcytosis: Crossing Cellular Barriers
TUMA, P. L., & HUBBARD, A. L. (2003) · Physiological Reviews · doi:10.1152/physrev.00001.2003 · Cited by 681 · see citing works
Conversion by Peyer's Patch Lymphocytes of Human Enterocytes into M Cells that Transport Bacteria
Kernéis, S. M., Bogdanova, A. A., Kraehenbühl, J.-P., & Pringault, E. (1997) · Science · doi:10.1126/science.277.5328.949 · Cited by 630 · see citing works
Size-Dependent Bioadhesion of Micro- and Nanoparticulate Carriers to the Inflamed Colonic Mucosa
Lamprecht, A., Schäfer, U., & Lehr, C.-M. (2001) · Pharmaceutical Research · doi:10.1023/a:1011032328064 · Cited by 507 · see citing works
Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier
Tang, B. C., Dawson, M., Lai, S. K., Wang, Y.-Y., Suk, J. S., Yang, M., Zeitlin, P., Boyle, M. P., Fu, J., & Hanes, J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905998106 · Cited by 453 · see citing works
Use of defined TLR ligands as adjuvants within human vaccines
Duthie, M. S., Windish, H. P., Fox, C. B., & Reed, S. G. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00978.x · Cited by 437 · see citing works
Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A
El-Shabouri, M. H. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00461-1 · Cited by 392 · see citing works
Cui, F., Shi, K., Zhang, L., Tao, A., & Kawashima, Y. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.05.013 · Cited by 391 · see citing works
Issues in long-term protein delivery using biodegradable microparticles
Ye, M., Kim, S., & Park, K. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.05.011 · Cited by 386 · see citing works
The mannose receptor: linking homeostasis and immunity through sugar recognition
TAYLOR, P., GORDON, S., & MARTINEZPOMARES, L. (2005) · Trends in Immunology · doi:10.1016/j.it.2004.12.001 · Cited by 368 · see citing works
Clark, M. A., Hirst, B. H., & Jepson, M. A. (1998) · Infection and Immunity · doi:10.1128/iai.66.3.1237-1243.1998 · Cited by 363 · see citing works
Owen, R. L., Pierce, N. F., Apple, R. T., & Cray, W. C. (1986) · The Journal of Infectious Diseases · doi:10.1093/infdis/153.6.1108 · Cited by 350 · see citing works
PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination
Garinot, M., Fiévez, V., Pourcelle, V., Stoffelbach, F., des Rieux, A., Plapied, L., Theate, I., Freichels, H., Jérôme, C., Marchand-Brynaert, J., et al. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.04.021 · Cited by 331 · see citing works
M-cells: origin, morphology and role in mucosal immunity and microbial pathogenesis
Corr, S. C., Gahan, C. C. G. M., & Hill, C. (2008) · FEMS Immunology & Medical Microbiology · doi:10.1111/j.1574-695x.2007.00359.x · Cited by 320 · see citing works
M Cells in Peyer's Patches of the Intestine
Gebert, A., Rothkötter, H., & Pabst, R. (1996) · International review of cytology · doi:10.1016/s0074-7696(08)61346-7 · Cited by 319 · see citing works
Formulation aspects of biodegradable polymeric microspheres for antigen delivery
Tamber, H., Johansen, P., Merkle, H. P., & Gander, B. A. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.09.002 · Cited by 318 · see citing works
Kanchan, V., & Panda, A. K. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2007.08.015 · Cited by 283 · see citing works
Cruz, L. J., Tacken, P. J., Fokkink, R., Joosten, B., Stuart, M. C., Albericio, F., Torensma, R., & Figdor, C. G. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.02.013 · Cited by 281 · see citing works
Expression of specific markers and particle transport in a new human intestinal M-cell model
Gullberg, E., Leonard, M., Karlsson, J., Hopkins, A. M., Brayden, D., Baird, A. W., & Artursson, P. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.4038 · Cited by 270 · see citing works
Immunity and correlates of protection for rotavirus vaccines
Franco, M. A., Angel, J., & Greenberg, H. B. (2006) · Vaccine · doi:10.1016/j.vaccine.2005.12.048 · Cited by 268 · see citing works
Sahana, D. K., Mittal, G., Bhardwaj, V., & Kumar, M. N. V. R. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21158 · Cited by 260 · see citing works
Hariharan, S., Bhardwaj, V., Bala, I., Sitterberg, J., Bakowsky, U., & Ravi Kumar, M. N. V. (2006) · Pharmaceutical Research · doi:10.1007/s11095-005-8418-y · Cited by 257 · see citing works
Neutra, M., Phillips, T., Mayer, E., & Fishkind, D. (1987) · Cell and Tissue Research · doi:10.1007/bf00215747 · Cited by 253 · see citing works
Preparation of porous and nonporous biodegradable polymeric hollow microspheres
Crotts, G., & Park, T. G. (1995) · Journal of Controlled Release · doi:10.1016/0168-3659(95)00010-6 · Cited by 253 · see citing works
Nanoparticle uptake by the oral route: Fulfilling its potential?
Florence, A. T. (2005) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2005.05.019 · Cited by 248 · cited 2× · see citing works
“33 Florence AT. Nanoparticle uptake by the oral route: fulfilling its potential? Drug Discov. Today Technol. 2(1), 75–81 (2005).”
BackgroundThe lectin–cell interaction and its implications to intestinal lectin-mediated drug delivery
Gabor, F., Bogner, E., Weissenboeck, A., & Wirth, M. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2003.10.015 · Cited by 247 · see citing works
Self-citationKim, H. K., Chung, H. J., & Park, T. G. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.02.004 · Cited by 247 · see citing works
Kalaria, D. R., Sharma, G., Beniwal, V., & Ravi Kumar, M. N. V. (2009) · Pharmaceutical Research · doi:10.1007/s11095-008-9763-4 · Cited by 246 · see citing works
Rhee, M., Valencia, P. M., Rodriguez, M. I., Langer, R., Farokhzad, O. C., & Karnik, R. (2011) · Advanced Materials · doi:10.1002/adma.201004333 · Cited by 236 · see citing works
Lectin-mediated mucosal delivery of drugs and microparticles
Clark, M. A., Hirst, B. H., & Jepson, M. A. (2000) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00070-3 · Cited by 236 · see citing works
Preferential interaction of Salmonella typhimurium with mouse Peyer's patch M cells
Clark, M. A., Jepson, M. A., Simmons, N. L., & Hirst, B. H. (1994) · Research in Microbiology · doi:10.1016/0923-2508(94)90031-0 · Cited by 235 · see citing works
Jain, A. K., Swarnakar, N. K., Godugu, C., Singh, R. P., & Jain, S. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2010.09.037 · Cited by 232 · see citing works
Jensen, V. B., Harty, J. T., & Jones, B. D. (1998) · Infection and Immunity · doi:10.1128/iai.66.8.3758-3766.1998 · Cited by 217 · see citing works
Microparticles as vaccine adjuvants and delivery systems
O’Hagan, D. T., & Singh, M. (2003) · Expert Review of Vaccines · doi:10.1586/14760584.2.2.269 · Cited by 214 · see citing works
Italia, J. L., Bhatt, D. K., Bhardwaj, V., Tikoo, K., & Kumar, M. N. V. R. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.02.004 · Cited by 203 · see citing works
Steenblock, E. R., & Fahmy, T. M. (2008) · Molecular Therapy · doi:10.1038/mt.2008.11 · Cited by 187 · see citing works
The immune effects of naturally occurring and synthetic nanoparticles
Chang, C. (2010) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.11.009 · Cited by 180 · cited 1× · see citing works
“62 Chang C. The immune effects of naturally occurring and synthetic nanoparticles. J. Autoimmun. 34(3), J234–J246 (2010).”
BackgroundEnhancing Oral Vaccine Potency by Targeting Intestinal M Cells
Azizi, A., Kumar, A., Diaz-Mitoma, F., & Mestecky, J. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001147 · Cited by 180 · see citing works
Hung, L.-H., Teh, S.-Y., Jester, J., & Lee, A. P. (2010) · Lab on a Chip · doi:10.1039/c002866e · Cited by 171 · see citing works
M cells and the pathogenesis of mucosal and systemic infections
Siebers, A., & Finlay, B. B. (1996) · Trends in Microbiology · doi:10.1016/0966-842x(96)81501-0 · Cited by 169 · see citing works
Shakweh, M., Besnard, M., Nicolas, V., & Fattal, E. (2005) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2005.04.006 · Cited by 161 · see citing works
Human Intestinal M Cells Display the Sialyl Lewis A Antigen
Giannasca, P. J., Giannasca, K. T., Leichtner, A. M., & Neutra, M. R. (1999) · Infection and Immunity · doi:10.1128/iai.67.2.946-953.1999 · Cited by 155 · see citing works
The impact of nanoparticle ligand density on dendritic-cell targeted vaccines
Bandyopadhyay, A., Fine, R. L., Demento, S., Bockenstedt, L. K., & Fahmy, T. M. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2010.12.054 · Cited by 141 · see citing works
Raghuvanshi, R. S., Katare, Y. K., Lalwani, K., Ali, M. M., Singh, O., & Panda, A. K. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00342-3 · Cited by 140 · see citing works
Prior, S., Gander, B., Blarer, N., Merkle, H. P., Subirá, M. L., Irache, J. M., & Gamazo, C. (2002) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(01)00218-4 · Cited by 138 · see citing works
Claudin 4-targeted protein incorporated into PLGA nanoparticles can mediate M cell targeted delivery
Rajapaksa, T. E., Stover-Hamer, M., Fernandez, X., Eckelhoefer, H. A., & Lo, D. D. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.10.033 · Cited by 137 · see citing works
M-cell targeted biodegradable PLGA nanoparticles for oral immunization against hepatitis B
Gupta, P. N., Khatri, K., Goyal, A. K., Mishra, N., & Vyas, S. P. (2007) · Journal of Drug Targeting · doi:10.1080/10611860701637982 · Cited by 136 · see citing works
Castellanos, I. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00488-1 · Cited by 134 · see citing works
Eldridge, J. H., Meulbroek, J. A., Staas, J. K., Tice, T. R., & Gilley, R. M. (1989) · Springer eBooks · doi:10.1007/978-1-4757-2046-4_18 · Cited by 133 · see citing works
The role of M cells in mucosal immunity
Hathaway, L. J., & Kraehenbuhl*, J.-P. (2000) · Cellular and Molecular Life Sciences CMLS · doi:10.1007/pl00000693 · Cited by 131 · see citing works
M cell targeting by lectins: a strategy for mucosal vaccination and drug delivery
Jepson, M. A., Clark, M. A., & Hirst, B. H. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2003.10.018 · Cited by 130 · see citing works
Schulte, R., Kernéis, S. M., Klinke, S., Bartels, H., Preger, S., Kraehenbuhl, J.-P., Pringault, E., & Autenrieth, I. B. (2000) · Cellular Microbiology · doi:10.1046/j.1462-5822.2000.00047.x · Cited by 129 · see citing works
Gaumet, M., Gurny, R., & Delie, F. (2009) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2008.11.015 · Cited by 115 · see citing works
Berkland, C., Pack, D. W., & Kim, K. (. (2004) · Biomaterials · doi:10.1016/j.biomaterials.2004.01.018 · Cited by 114 · see citing works
Herrmann, J., & Bodmeier, R. A. (1998) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(97)00125-2 · Cited by 113 · see citing works
Thomasin, C., Nam‐Trân, H., Merkle, H. P., et al. (1998) · Journal of Pharmaceutical Sciences · doi:10.1021/js970047r · Cited by 113 · see citing works
Semete, B., Booysen, L. I. J., Kalombo, L., Venter, J. D., Katata, L., Ramalapa, B., Verschoor, J. A., & Swai, H. (2010) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2010.09.002 · Cited by 108 · see citing works
Tian, J., & Yu, J. (2011) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2010.09.016 · Cited by 107 · see citing works
Varma, M., Khandavilli, S., Ashokraj, Y., Jain, A., Dhanikula, A., Sood, A., Thomas, N., Pillai, O., Sharma, P., Gandhi, R., et al. (2004) · Current Drug Metabolism · doi:10.2174/1389200043335423 · Cited by 107 · see citing works
Interaction of Yersinia enterocolitica with epithelial cells: invasin beyond invasion
Graßl, G. A., Bohn, E., Muller, Y. M. F., et al. (2003) · International Journal of Medical Microbiology · doi:10.1078/1438-4221-00243 · Cited by 103 · see citing works
Helander, A., Silvey, K. J., Mantis, N. J., Hutchings, A. B., Chandran, K., Lucas, W. T., Nibert, M. L., & Neutra, M. R. (2003) · Journal of Virology · doi:10.1128/jvi.77.14.7964-7977.2003 · Cited by 102 · see citing works
Transepithelial transport of HIV-1 by M cells is receptor-mediated
Fotopoulos, G., Harari, A., Michetti, P., Trono, D., Pantaleo, G., & Kraehenbühl, J.-P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.142586899 · Cited by 101 · see citing works
Biodegradable polymer microspheres as vaccine adjuvants and delivery systems.
Rk, G., Chang, A. C., & Siber, G. R. (1998) · PubMed · Cited by 98 · see citing works
Schöll, I., Weissenböck, A., Förster‐Waldl, E., Untersmayr, E., Walter, F., Willheim, M., Boltz‐Nitulescu, G., Scheiner, O., Gabor, F., & Jensen‐Jarolim, E. (2004) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2004.01884.x · Cited by 95 · see citing works
Self-citationLectin anchored PLGA nanoparticles for oral mucosal immunization against hepatitis B
Mishra, N., Tiwari, S., Vaidya, B., Agrawal, G. P., & Vyas, S. P. (2011) · Journal of Drug Targeting · doi:10.3109/10611861003733946 · Cited by 94 · see citing works
Ruan, G., Feng, S.-S., & Li, Q.-T. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00292-4 · Cited by 93 · see citing works
Makhlof, A., Fujimoto, S., Tozuka, Y., & Takeuchi, H. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2010.12.008 · Cited by 90 · see citing works
Jain, A. K., Swarnakar, N. K., Das, M., Godugu, C., Singh, R. P., Rao, P. R., & Jain, S. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200011f · Cited by 89 · see citing works
Lectin-Induced Nitric Oxide Production
Andrade, J. L., Arruda, S., Barbosa, T., Paim, L., Ramos, M. V., Cavada, B. S., & Barral-Netto, M. (1999) · Cellular Immunology · doi:10.1006/cimm.1999.1494 · Cited by 86 · see citing works
Characterization of recombinant and plant‐derived mistletoe lectin and their B‐chains
Eck, J., Langer, M., Möckel, B., Witthohn, K., Zinke, H., & Lentzen, H. (1999) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1999.00784.x · Cited by 82 · see citing works
Diesner, S. C., Knittelfelder, R., Krishnamurthy, D., Pali-Schöll, I., Gajdzik, L., Jensen-Jarolim, E., & Untersmayr, E. (2008) · Immunology Letters · doi:10.1016/j.imlet.2008.08.006 · Cited by 81 · see citing works
Self-citationHillery, A. M., & Florence, A. T. (1996) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(95)04353-5 · Cited by 81 · see citing works
Thomann, J.-S., Heurtault, B., Weidner, S., Brayé, M., Beyrath, J., Fournel, S., Schuber, F., & Frisch, B. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.03.015 · Cited by 81 · see citing works
Thomas, C., Gupta, V., & Ahsan, F. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.06.006 · Cited by 79 · see citing works
Gabor, F., Stangl, M., & Wirth, M. (1998) · Journal of Controlled Release · doi:10.1016/s0168-3659(98)00043-1 · Cited by 78 · see citing works
Self-citationFunctional differences between M cells and enterocytes in sampling luminal antigens
Kyd, J. M., & Cripps, A. W. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.09.061 · Cited by 75 · see citing works
Targeted binding of PLA microparticles with lipid-PEG-tethered ligands
Duncanson, W. J., Figa, M. A., Hallock, K., Zalipsky, S., Hamilton, J. A., & Wong, J. Y. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2007.05.044 · Cited by 75 · see citing works
Specific and non-specific phagocytosis of ligand-grafted PLGA microspheres by macrophages
Brandhonneur, N., Chevanne, F., Vié, V., Frisch, B., Primault, R., Le Potier, M.-F., & Le Corre, P. (2009) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2008.11.013 · Cited by 75 · see citing works
Immunogenicity of single-dose diphtheria vaccines based on PLA/PLGA microspheres in guinea pigs
Johansen, P., Moon, L., Tamber, H., Merkle, H. P., Gander, B., & Sesardic, D. (1999) · Vaccine · doi:10.1016/s0264-410x(99)00191-7 · Cited by 71 · see citing works
Concanavalin A induced expression of Toll-like receptors in murine peritoneal macrophages in vitro
Sodhi, A., Tarang, S., & Kesherwani, V. (2007) · International Immunopharmacology · doi:10.1016/j.intimp.2006.11.014 · Cited by 67 · see citing works
Lee, H.-M., Shin, D.-M., Song, H.-M., Yuk, J.-M., Lee, Z.-W., Lee, S.-H., Hwang, S. M., Kim, J.-M., Lee, C.-S., & Jo, E.-K. (2009) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.05.010 · Cited by 67 · see citing works
Kim, S., Doh, H., Jang, M., Ha, Y., Chung, S., & Park, H. (1999) · Helicobacter · doi:10.1046/j.1523-5378.1999.09046.x · Cited by 65 · see citing works
Microparticle vaccine approaches to stimulate mucosal immunisation
Brayden, D. J., & Baird, A. W. (2001) · Microbes and Infection · doi:10.1016/s1286-4579(01)01445-9 · Cited by 64 · see citing works
A Protective Allergy Vaccine Based on CpG- and Protamine-Containing PLGA Microparticles
Gómez, J. M. M., Fischer, S., Csaba, N., Kündig, T. M., Merkle, H. P., Gander, B., & Johansen, P. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9318-0 · Cited by 63 · see citing works
The role of M cells of human nasopharyngeal lymphoid tissue in influenza virus sampling
Fujimura, Y., Takeda, M., 伊海, 英., Haruma, K., Akisada, T., Harada, T., Sakai, T., & Ohuchi, M. (2004) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-003-0898-8 · Cited by 63 · see citing works
Ertl, B., Heigl, F., Wirth, M., & Gabor, F. (2000) · Journal of drug targeting · doi:10.3109/10611860008996863 · Cited by 60 · see citing works
Self-citationLuzardo-Alvarez, A., Blarer, N., Peter, K., Romero, J. F., Reymond, C., Corradin, G., & Gander, B. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.09.015 · Cited by 59 · see citing works
Use of fluorescence imaging to investigate the structure and function of intestinal M cells
BUDA, A. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.07.014 · Cited by 59 · see citing works
Kerneis, S., Bogdanova, A., Colucci-Guyon, E., Kraehenbuhl, J., & Pringault, E. (1996) · Gastroenterology · doi:10.1053/gast.1996.v110.pm8566599 · Cited by 59 · see citing works
Wattendorf, U., Coullerez, G., Vörös, J., Textor, M., & Merkle, H. P. (2008) · Langmuir · doi:10.1021/la801085d · Cited by 58 · see citing works
M cell targeting with Aleuria aurantia lectin as a novel approach for oral allergen immunotherapy
Roth-Walter, F., Schöll, I., Untersmayr, E., Fuchs, R., Boltz-Nitulescu, G., Weissenböck, A., Scheiner, O., Gabor, F., & Jensen-Jarolim, E. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.08.010 · Cited by 58 · see citing works
Self-citationNayak, B., Panda, A. K., Ray, P., & Ray, A. R. (2009) · Journal of Microencapsulation · doi:10.1080/02652040802211709 · Cited by 57 · see citing works
Mucosal targeting of allergen-loaded microspheres by Aleuria aurantia lectin
Roth-Walter, F., Schöll, I., Untersmayr, E., Ellinger, A., Boltz-Nitulescu, G., Scheiner, O., Gabor, F., & Jensen-Jarolim, E. (2005) · Vaccine · doi:10.1016/j.vaccine.2004.11.052 · Cited by 55 · see citing works
Self-citationFelder, C. B., Blanco-Príeto, M. J., Heizmann, J., Merkle, H. P., & Gander, B. (2003) · Journal of Microencapsulation · doi:10.3109/02652040309178346 · Cited by 55 · see citing works
Targeted Delivery of Immunogen to Primate M Cells with Tetragalloyl Lysine Dendrimer
Misumi, S., Masuyama, M., Takamune, N., Nakayama, D., Mitsumata, R., Matsumoto, H., Urata, N., Takahashi, Y., Muneoka, A., Sukamoto, T., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802928 · Cited by 53 · see citing works
Schöll, I., Boltz-Nitulescu, G., & Jensen-Jarolim, E. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.12.020 · Cited by 51 · see citing works
Self-citationValidation and quantitation of an in vitro M-cell model
Tyrer, P., Ruth Foxwell, A., Kyd, J., Harvey, M., Sizer, P., & Cripps, A. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02631-1 · Cited by 51 · see citing works
Hanlon, D. J., Aldo, P. B., Devine, L., et al. (2011) · American Journal of Reproductive Immunology · doi:10.1111/j.1600-0897.2010.00968.x · Cited by 51 · see citing works
Torché, A.-M., Le Corre, P., Albina, E., & Le Verge, R. (1999) · Journal of Drug Targeting · doi:10.3109/10611869909085517 · Cited by 50 · see citing works
Walter, F., Schöll, I., Untersmayr, E., Ellinger, A., Boltz-Nitulescu, G., Scheiner, O., Gabor, F., & Jensen-Jarolim, E. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.01.057 · Cited by 47 · see citing works
Self-citationMa, W., Smith, T. R. F., Bogin, V., et al. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-34 · Cited by 46 · see citing works
Apical membrane receptors on intestinal M cells: potential targets for vaccine delivery
Brayden, D. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2003.10.036 · Cited by 43 · see citing works
Roth-Walter, F., Bohle, B., Schöll, I., Untersmayr, E., Scheiner, O., Boltz-Nitulescu, G., Gabor, F., Brayden, D. J., & Jensen-Jarolim, E. (2005) · Immunology Letters · doi:10.1016/j.imlet.2005.03.020 · Cited by 42 · see citing works
Self-citationGaumet, M., Gurny, R., & Delie, F. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.10.008 · Cited by 42 · see citing works
Wirth, M., Hamilton, G., & Gabora, F. (1998) · Journal of Drug Targeting · doi:10.3109/10611869808997885 · Cited by 41 · see citing works
Biodegradable PLGA Particles for Improved Systemic and Mucosal Treatment of Type I Allergy
Schöll, I., Kopp, T., Bohle, B., & Jensen-Jarolim, E. (2006) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2006.02.007 · Cited by 40 · see citing works
Self-citationLambkin, I., Pinilla, C., Hamashin, C., Spindler, L., Russell, S., Schink, A., Moya-Castro, R., Allicotti, G., Higgins, L., Smith, M., et al. (2003) · Pharmaceutical Research · doi:10.1023/a:1025061317400 · Cited by 39 · see citing works
Felder, C. B., Blanco‐Prieto, M. J., Heizmann, J., et al. (2003) · Journal of Microencapsulation · doi:10.1080/0265204031000148059 · Cited by 39 · see citing works
TAKATA, S., OHTANI, O., & WATANABE, Y. (2000) · Archives of Histology and Cytology · doi:10.1679/aohc.63.305 · Cited by 38 · see citing works
DC-SIGN mediated antigen-targeting using glycan-modified liposomes: Formulation considerations
Joshi, M. D., Unger, W. W. J., van Beelen, A. J., Bruijns, S. C., Litjens, M., van Bloois, L., Kalay, H., van Kooyk, Y., & Storm, G. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.02.055 · Cited by 38 · see citing works
Peyre, M., Sesardic, D., Merkle, H. P., Gander, B., & Johansen, P. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10361 · Cited by 36 · see citing works
FREITAS, S., RUDOLF, B., MERKLE, H., & GANDER, B. (2005) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2005.05.004 · Cited by 36 · see citing works
Batanero, E. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(03)00337-7 · Cited by 31 · see citing works
Leo, E., Ruozi, B., Tosi, G., & Vandelli, M. A. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.05.047 · Cited by 31 · see citing works
Han, H., Peng, J., Chen, P.-C., Gong, L., Qiao, S., Wang, W., Cui, Z.-Q., Yu, X., Wei, Y., & Leng, X.-S. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.06.164 · Cited by 24 · see citing works
The Role of Surface Functionalization in the Design of PLGA Micro- and Nanoparticles
Ratzinger, G., Fillafer, C., Kerleta, V., Wirth, M., & Gabor, F. (2010) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v27.i1.10 · Cited by 22 · see citing works
Self-citationThe immunopathology of M cells
Davis, I. C., & Owen, R. L. (1997) · Springer Seminars in Immunopathology · doi:10.1007/bf00824051 · Cited by 21 · see citing works
Pohlmeyer, I., Jörns, J., Schumacher, U., Van Damme, E. J. M., Peumans, W. J., Pfüller, U., & Neumann, U. (2005) · Journal of Veterinary Medicine Series A · doi:10.1111/j.1439-0442.2005.00696.x · Cited by 20 · see citing works
Igartua, M., Hernández, R. M., Gutierro, I., Gascón, A. R., & Pedraz, J. L. (2001) · Pharmaceutical Development and Technology · doi:10.1081/pdt-120000299 · Cited by 12 · see citing works
León-Rodriguez, L., Leiro-Vidal, J., Blanco-Méndez, J., & Luzardo-Álvarez, A. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.10.006 · Cited by 11 · see citing works
Improved Immunogenicity of Biodegradable Polymer Particles Entrapped Rotavirus Vaccine
Nayak, B., Ray, A. R., Panda, A. K., & Ray, P. (2011) · Journal of Biomaterials Applications · doi:10.1177/0885328209353642 · Cited by 10 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- Hermanson GT . Bioconjugate Techniques. Academic Press San Diego CA USA 170–176 (1996).
Cited by
Sorted by citations
Hua, S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00524 · Cited by 565 · see citing works
Application of immunostimulants in aquaculture: current knowledge and future perspectives
Wang, W., Sun, J., Liu, C., & Xue, Z. (2016) · Aquaculture Research · doi:10.1111/are.13161 · Cited by 372 · see citing works
“In a recent study, the potential use of lectins as immunostimulants was investigated in Japanese flounder (Diesner, Wang, Jensen-Jarolim, Untersmayr & Gabor 2012).”
BackgroundPlant protein-based hydrophobic fine and ultrafine carrier particles in drug delivery systems
Malekzad, H., Mirshekari, H., Zangabad, P. S., Basri, S. M. M., Baniasadi, F., Aghdam, M. S., Karimi, M., & Hamblin, M. R. (2017) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2017.1312267 · Cited by 115 · see citing works
“[139,146,167,173,174], oral antigen delivery [152,175],”
Adding Functions to Biomaterial Surfaces through Protein Incorporation
Wrońska, M. A., O’Connor, I. B., Tilbury, M. A., Srivastava, A., & Wall, J. G. (2016) · Advanced Materials · doi:10.1002/adma.201504310 · Cited by 84 · see citing works
Joshi, V. B., Geary, S. M., & Salem, A. K. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.26136 · Cited by 83 · see citing works
Ligand-mediated active targeting for enhanced oral absorption
Zhang, X., & Wu, W. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.03.001 · Cited by 78 · see citing works
Advanced oral vaccine delivery strategies for improving the immunity
Zhang, Y., Li, M., Du, G., Chen, X., & Sun, X. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113928 · Cited by 74 · see citing works
Sharma, S., Verma, A., Singh, J., Teja, B. V., Mittapelly, N., Pandey, G., Urandur, S., Shukla, R. P., Konwar, R., & Mishra, P. R. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b08958 · Cited by 60 · see citing works
Cao, P., Xu, Z. P., & Li, L. (2022) · Composites Part B Engineering · doi:10.1016/j.compositesb.2022.109826 · Cited by 57 · see citing works
Kumar, V. P., & Venkatesh, Y. P. (2016) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2016.04.006 · Cited by 52 · see citing works
Johnson, L., Duschl, A., & Himly, M. (2020) · Vaccines · doi:10.3390/vaccines8020237 · Cited by 53 · see citing works
“This functionalization approach was efficient in targeting enterocytes, thereby improving uptake and preventing degradation of the delivered antigen through gastrointestinal enzymes [84].”
BackgroundBarhate, G., Gautam, M., Gairola, S., et al. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.10.033 · Cited by 51 · see citing works
Exploiting or overcoming the dome trap for enhanced oral immunization and drug delivery
Qi, J., Zhuang, J., Lv, Y., Lü, Y., & Wu, W. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.02.021 · Cited by 43 · see citing works
Pharmaceutical applications of lectins
de Juan, L. L., García-Recio, V., López, P. J., Juan, T. G., Córdoba-Díaz, M., & Córdoba-Díaz, D. (2017) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2017.05.018 · Cited by 35 · see citing works
Ahmed, K. B. A., Mohammed, A. S., & Veerappan, A. (2015) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2015.01.133 · Cited by 28 · see citing works
Plant Lectins: Bioactivities and Bioapplications
Ribeiro, A. C., Ferreira, R. B., & Freitas, R. L. (2018) · Studies in natural products chemistry · doi:10.1016/b978-0-444-64056-7.00001-5 · Cited by 26 · see citing works
Yang, C., Sharma, K., Mow, R. J., Bolay, E., Srinivasan, A., & Merlin, D. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2024.03.005 · Cited by 25 · see citing works
“45 Studies using lectin-functionalized NPs demonstrated higher M-cell uptake in vitro and increased localization in Peyer ’ s patches in vivo, 63 emphasizing the potential of these strategies for oral NP delivery to treat IBD.”
BackgroundBiomedical applications of PLGA particles
Agrawal, A., Rellegadla, S., & Jain, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816913-1.00004-0 · Cited by 23 · see citing works
Alocasia cucullata Exhibits Strong Antitumor Effect In Vivo by Activating Antitumor Immunity
Peng, Q., Cai, H., Sun, X., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075328 · Cited by 17 · see citing works
“The active components that may account for AC’s pharmacological effects possibly include amino acids and polysaccharides [14], which both have been shown to have immuno-stimulatory effects [16,17].”
BackgroundAhmed, K. B. A., Reshma, E., Mariappan, M., et al. (2014) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2014.09.047 · Cited by 16 · see citing works
Corzo, C., Fuchsbichler, A., Savencu, I., et al. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121259 · Cited by 15 · see citing works
Exploring plant lectins in diagnosis, prophylaxis and therapy
Majee, S. B., & Biswas, G. R. (2013) · Journal of Medicinal Plants Research · doi:10.5897/jmpr2013.5289 · Cited by 15 · see citing works
“Pharmacological efficacy of calcitonin has been improved by Carbopol-based nanocarriers whose surface was modified by WGA (Diesner et al., 2012).”
BackgroundInfluentialOsterne, V. J. S., Verduijn, J., Lóssio, C. F., et al. (2022) · Journal of Materials Science · doi:10.1007/s10853-022-07230-8 · Cited by 14 · see citing works
“[59] Diesner SC, Wang XY, Jensen-Jarolim E, Untersmayr E, Gabor F (2012) Use of lectin-functionalized particles for oral”
BackgroundLipid‐enveloped PLGA as a hybrid carrier for sustained delivering camptothecin in ovarian cancer
Lin, Y., Gao, M., Wu, Y., et al. (2017) · IET Nanobiotechnology · doi:10.1049/iet-nbt.2016.0141 · Cited by 12 · see citing works
Advances in Early Detection and Diagnostic Adjuncts in Oral Cavity Cancer
Farah, C. S., Bhatia, N., Lalla, Y., et al. (2016) · doi:10.1007/978-3-319-14911-0_9 · Cited by 12 · see citing works
Allergy Treatment: A Comprehensive Review of Nanoparticle-based Allergen Immunotherapy
Abo‐Zaid, M. A., Elsapagh, R. M., Sultan, N. S., Mawkili, W., Hegazy, M. M., & Ismail, A. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl26550 · Cited by 11 · see citing works
“Polylactic-co-glycolic acid particles functionalized with lectin are suggested as effective platforms for oral anionic immunotherapy (AIT), improving the absorption of allergens and increasing their resistance to breakdown in the gastrointestinal tract [149].”
Nano-bio-encapsulation of phyto-vaccines: a breakthrough in targeted cancer immunotherapy
Ayyadurai, P., & Ragavendran, C. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-10164-w · Cited by 9 · see citing works
Pali‐Schöll, I., DeBoer, D. J., Alessandri, C., Seida, A. A., Mueller, R. S., & Jensen‐Jarolim, E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01697 · Cited by 10 · see citing works
Self-citationDiesner, S. C., Bergmayr, C., Wang, X.-Y., Heiden, D., Exenberger, S., Roth-Walter, F., Starkl, P., Ret, D., Pali-Schöll, I., Gabor, F., et al. (2018) · Clinical Immunology · doi:10.1016/j.clim.2018.03.017 · Cited by 9 · see citing works
“For oral application, drugs have to fulfill several criteria, such as digestion stability and sufficient bioavailability by overcoming the first pass metabolism [2].”
BackgroundSelf-citationUse of lectin-functionalized and lectin-targeted nanoparticles for multiple therapeutic applications
Mol, K. R. R., & Hatha, A. A. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-820557-0.00023-0 · Cited by 5 · see citing works
Protein and peptide nanostructures for drug and gene delivery
Krishnan, U. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-08-102850-6.00013-9 · Cited by 4 · see citing works
Nanoparticulate drug delivery systems for the oral administration of macromolecular drugs
Iqbal, J., Behl, G., Walker, G., Edin, C., Kumar, P., O’Reilly, N. J., Bhatia, R., Fitzhenry, L., & Arora, T. K. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816504-1.00017-x · Cited by 5 · see citing works
Determination of the glycosylation-pattern of the middle ear mucosa in guinea pigs
Engleder, E., Demmerer, E., Wang, X., et al. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.02.056 · Cited by 4 · see citing works
“, 2010), and the lymphoid tissue (Diesner et al., 2012).”
Self-citationAbdelazeem, M., Mohamed, M. I., & Akl, M. A. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.106433 · Cited by 3 · see citing works
Gausterer, J. C., Schlager, M., Ahmadi, N., Nieratschker, M., Dahm, V., Wirth, M., Arnoldner, C., Honeder, C., & Gabor, F. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030973 · Cited by 3 · see citing works
Self-citationDistribution patterns of carbohydrates in murine glycocalyx
Pavlova, V., Paunova-Krasteva, T. S., Stoitsova, S. R., & Николова, Е. (2015) · Biotechnology & Biotechnological Equipment · doi:10.1080/13102818.2014.999214 · Cited by 3 · see citing works
“The precise carbohydrate covering of human intestinal M cells is, however, still under investigation.[7,8] Wheat germ agglutinin (WGA) is a nontoxic lectin which is derived from wheat flour and is highly resistant against gastric digestion.”
BackgroundNajafi, K., Jojani, M., Najafi, S., & Roviello, G. (2026) · Vaccines · doi:10.3390/vaccines14050391 · Cited by 3 · see citing works
Nandhakumar, Jimsha, E. V., Wangkahart, E., et al. (2026) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2026.111184
Applications of nanotechnology in allergy and asthma
Pervaiz, S., Cheema, S. M., Shaheen, T., Tahir, R., Haider, Z., & Shamim, S. (2023) · Journal of Basic & Clinical Medical Sciences · doi:10.58398/0002.000008
Biodegradable particles as vaccine delivery systems
Joshi, V. B., Salem, A. K., Donovan, M. D., Flanagan, D. R., Thorne, P. S., & Stevens, L. L. (2014) · doi:10.17077/etd.q3wwcov7
- Authors
- Diesner, S. C., Wang, X.-Y., Jensen-Jarolim, E., Untersmayr, E., & Gabor, F.
- Affiliations
- Medical University of Vienna (AT)
- Department of Pharmaceutical Technology & Biopharmaceutics University of Vienna Althanstrasse 14 Vienna 1090 Austria
- Department of Pathophysiology & Allergy Research Center of Pathophysiology Immunology & Infectiology Medical University of Vienna Vienna Austria
- University of Vienna (AT)
- Corresponding author
- Gabor, Franz
- Venue
- Therapeutic Delivery
- Publisher
- Informa UK Limited
- Published
- 2012-02
- Volume
- 3
- Issue
- 2
- Pages
- 277-290
- ISSN
- 2041-5990 (ISSN-L)
- 2041-6008
- PMC
- PMC3572827
- OpenAlex
- W2035801110
- Cited by
- 40
- References
- 130
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 3 · 2023: 3 · 2022: 2 · 2021: 2 · 2020: 4 · 2019: 2 · 2018: 3 · 2017: 3 · 2016: 5 · 2015: 3 · 2014: 3 · 2013: 3 · 2012: 1
- FWCI
- 0.40
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Therapeutic Delivery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Austrian Science Fund
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- oral immunotherapy, polymer particles, antigen encapsulation, mucosal immune response, Aleuria aurantia lectin, wheat germ agglutinin, Ulex europaeus I lectin, mucosa-associated lymphoid tissue, transepithelial transport, antigen-presenting cells, bioavailability, immune-mediated diseases
- MeSH terms
- Polylactic Acid-Polyglycolic Acid Copolymer, Administration, Oral, Animals, Antigens, Biological Availability, Biological Transport, Drug Carriers, Humans, Immunologic Factors, Immunotherapy, Intestinal Absorption, Intestinal Mucosa, Intestines, Polyglycolic Acid, Immunity, Mucosal, Lactic Acid, Lectins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Claims read under definition version 3 (extract-v3) on 2026-09-28.
Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-09-28.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review